Eng

Bazi Bushen Capsule Became the Representative Drug of Anti-aging Chinese Medicine

PR Newswire (美通社)
更新於 04月25日08:42 • 發布於 04月25日08:07 • PR Newswire

SHIJIAZHUANG, China, April 25, 2024 /PRNewswire/ -- On April 21, the 3rd Traditional Chinese Medicine Anti-Aging Conference, hosted by the World Federation of Chinese Medicine Societies, was held in Shijiazhuang. Yiling Pharmaceutical's Bazi Bushen capsule, as a representative drug of anti-aging innovative TCM widely recognized in the industry, became one of the focuses of the meeting. At the conference, many experts and scholars shared the theoretical basis and clinical research results of Bazi Bushen capsule in detail, and the effectiveness of the product in anti-aging has been recognized by many participants.

The 3rd Traditional Chinese Medicine Anti-Aging Conference

The 3rd Traditional Chinese Medicine Anti-Aging Conference

廣告(請繼續閱讀本文)

Liu Yanhong, Deputy Director of Hebei Provincial Administration of Traditional Chinese Medicine, remarked that anti-aging is an eternal topic in human health and currently one of the hottest research areas in life sciences. The research on vital energy and spirit for anti-aging led by Academician Wu Yiling has provided a new direction and path for the construction of new theories of Traditional Chinese medicine anti-aging, leveraging new advantages in anti-aging, actively addressing population aging, and exploring new pathways to promote the construction of a healthy China.

Academician Wu Yiling’s Academic Report

Academician Wu Yiling’s Academic Report

廣告(請繼續閱讀本文)

During the conference, Wu delivered an academic report entitled Study on Anti-Aging of Bazi Bushen Capsules Guided by the Theory of Qi and Meridians and the Theory of Vital Energy and Spirit. It is understood that in recent years, Wu has led a team of experts to conduct systematic research on kidney-tonifying prescriptions from over two thousand years ago under the guidance of the theory of Qi and meridians and the theory of vital energy and spirit, and through inheritance and innovation, they have successfully created Bazi Bushen Capsules. Series of studies have found that Bazi Bushen Capsules have significant preventive and therapeutic effects on aging-related diseases of various systems including the nervous, circulatory, digestive, respiratory, immune, reproductive, motor, and integumentary systems. Concurrent clinical evidence-based study has also confirmed the anti-aging effects of Bazi Bushen Capsules, which can significantly relieve the aging symptoms of the nervous, mental, integumentary, musculoskeletal and urogenital systems in the elderly, improve physical and psychological frailty, enhance the quality of life, and increase exercise capacity and endurance.

References:

Bazi Bushen mitigates epigenetic aging and extends healthspan in naturally aging mice
Biomedicine & Pharmacotherapy, 160 (2023).

廣告(請繼續閱讀本文)

BaZiBuShen alleviates cognitive deficits and regulates Sirt6/NRF2/HO-1 and Sirt6/P53-PGC-1α-TERT signaling pathways in aging mice
Journal of Ethnopharmacology, 282 (2022).

BaZiBuShen alleviates altered testicular morphology and spermatogenesis and modulates Sirt6/P53 and Sirt6/NF-κB pathways in aging mice induced by D-galactose and NaNO2
Journal of Ethnopharmacology, 271 (2021).

Bazi Bushen alleviates skin senescence by orchestrating skin homeostasis in SAMP6 mice
Journal of Cellular and Molecular Medicine, 27 (2023).

查看原始文章

更多 Eng 相關文章

Russia's Progress MS-27 cargo spacecraft docks at ISS
XINHUA
Update: China's Chang'e-6 lands on moon's far side to collect samples
XINHUA
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
PR Newswire (美通社)
Han Wei clinches 4th championship as Taklimakan Rally concludes
XINHUA
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
PR Newswire (美通社)
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
PR Newswire (美通社)
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
PR Newswire (美通社)
Asia Album: Travel with China's train at Asia Pacific Rail 2024
XINHUA
China's C919 serves first overseas commercial chartered flight
XINHUA
A traumatized Iraqi child struggles to overcome hardships after years of violence
XINHUA
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting
PR Newswire (美通社)
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
PR Newswire (美通社)